🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Learn from literally the BEST in cancer biology informatics👇🏽 As a cancer researcher if you haven’t taken a look cBioPortal - do so NOW. If you don’t understand it, watch their webinars. Incredibly important tool to get familiar with. Also go to Ritika Kundra #AACR22 talk!!

New OncoKB™ release people! -KMT2A fusions & NPM1 mut level 3A based on compelling clinical activity of menin inh in pts w/ AML -ALK fusions are FINALLY level 1 in inflammatory myofibroblastic tumors! [PS. We're hiring! bit.ly/3RYqXn1]

Great opportunity to work in the field of precision medicine with a wonderful team of scientists at one of the top cancer hospitals!

New OncoKB™ release people! 7 yrs post David Hyman & Jose Baselga's BRAF V600E basket trial, BRAF V600E is now Level 1 in all solid tumors ➡️ 4th U.S. FDA recognized tumor agnostic biomarker after NTRK fusions, MSI-H & TMB-H Another 1st? ERBB2 oncogenic mut are Level 1 in #lungcancer

OncoKB™ release people & >700 cancer genes curated to date! What a great way to join our team OncoKB™ scientists Amanda Dhaneshwar & Nicole Fernandez!! 👏 Ritika Kundra too! Also stay tuned for OncoKB™ releases w/every new FDA targeted drug approval or NCCN precision oncology update!

GAME CHANGING OncoKB™ release just in time for #AACR23! Introducing pages w/ the clinical implications of a mutation found in specific cancers & incl descriptions of the trial data underpinning level assignments (eg ALK fusions in IMT): oncokb.org/gene/ALK/Fusio… You're welcome!

People - I know it’s the last day of #AACR23 - but finish it w/ bang! Visit our Senior Scientist Moriah Heller Nissan, PhD in Section 13 (West side) poster #18 to see our OncoKB™ poster & here about the latest developments we’re working on.

Better late that never -- new OncoKB™ release people! Steadily increasing our gene curation &1 new U.S. FDA approval of Dostarlimab + Carboplatin + Paclitaxel for MSI-H+ endometrial ca Prepping for our meeting w/ our Clinical Genomics Annotation Committee & Ext Advisory Board!

Check out our 2nd OncoKB™ paper bit.ly/46X72vj Since 1998, 43% of all oncology drugs are precision oncology drugs=biomarker testing req'd for tx eligibility From 2017-2022:~4X ⏫ in std care actionability based on mut found in a pt solid tumor cohort Tweetorial next..

From the January issue— Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer, by Sarah Phillips Suehnholz, Debyani Chakravarty, PhD 🇺🇦 et al. bit.ly/3Seg5lE OncoKB™ Memorial Sloan Kettering Cancer Center #PrecisionOncology

New OncoKB data release v4.16: Release of CDx page incl biomarker, cancer type, drug & specimen type. BRAF fusions & V600 mts L1 in LGG. ERBB2 amp L2 in salivary gland cancer & L3A in solid tumors, the latter following FDA-approval of T-DXd for HER2+ (IHC3+) tumors + 7 new genes

Join us May 31-June 4 at the ASCO 2024 Annual meeting in Chicago at Booth # 37106 to meet our team, explore our latest developments and learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB licensing and content!

Stop by the OncoKB™ booth (#37106) today to learn more about their latest developments. ⬇️#ASCO24